Status:
RECRUITING
Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT
Lead Sponsor:
Yi Zhang
Collaborating Sponsors:
The First People's Hospital of Yunnan
The First Affiliated Hospital of Zhengzhou University
Conditions:
Moxibustion
Hematopoietic Stem Cell Transplantation
Eligibility:
All Genders
14-60 years
Phase:
NA
Brief Summary
This study was a prospective, multicenter, randomized controlled clinical study planned to recruit 266 hematological patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT), who w...
Eligibility Criteria
Inclusion
- Patients are fully aware of the study, participate voluntarily and sign the informed consent form (ICF);
- Age: 14-60 years;
- Patients with pernicious blood diseases undergoing allo-HSCT using the MAC protocol or patients with severe aplastic anemia (Severe aplastic anemia; severeaplasticanimin, SAA) undergoing allo-HSCT;
Exclusion
- refuse to participate in this clinical study;
- The corresponding skin at the moxibustion site is broken or sensitive;
- allo-HSCT pretreated with the RIC program;
Key Trial Info
Start Date :
March 21 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
266 Patients enrolled
Trial Details
Trial ID
NCT06198517
Start Date
March 21 2024
End Date
June 30 2026
Last Update
February 20 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Zhengzhou, Henan, China, 450002
2
Yi Zhang
Wuhan, Hubei, China, 430000
3
Hematology Department, The First People's Hospital of Yunnan
Kunming, Yunnan, China, 650032
4
Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Hangzhou, Zhejiang, China, 311121